tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target
PremiumRatingsCrescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target
16d ago
Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial
Premium
The Fly
Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial
17d ago
Crescent Biopharma initiated with an Overweight at Piper Sandler
Premium
The Fly
Crescent Biopharma initiated with an Overweight at Piper Sandler
1M ago
Crescent Biopharma announces regulatory clearance of IND applications
PremiumThe FlyCrescent Biopharma announces regulatory clearance of IND applications
2M ago
Two new option listings and eighteen option delistings on December 22nd
Premium
The Fly
Two new option listings and eighteen option delistings on December 22nd
2M ago
Crescent Biopharma’s Strategic Growth and Competitive Edge Justify Buy Rating
Premium
Ratings
Crescent Biopharma’s Strategic Growth and Competitive Edge Justify Buy Rating
3M ago
Crescent Biopharma’s Promising Future: Buy Rating Backed by CR-001’s Clinical Potential and Strong IP Position
PremiumRatingsCrescent Biopharma’s Promising Future: Buy Rating Backed by CR-001’s Clinical Potential and Strong IP Position
4M ago
Crescent Biopharma Advances Cancer Therapy Pipeline
Premium
Company Announcements
Crescent Biopharma Advances Cancer Therapy Pipeline
4M ago
Crescent Biopharma’s Promising Pipeline and Strategic Progress Drive Buy Rating
Premium
Ratings
Crescent Biopharma’s Promising Pipeline and Strategic Progress Drive Buy Rating
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100